Given the function of LAIR-1 as an immune checkpoint inhibitor and its interaction with collagens, inhibiting both the increase of LAIR-1 and the increase in collagen I, in combination with PD-1/PD-L1 therapy, could have a beneficial effect in tumours expressing high levels of collagen in the tumour microenvironment. This evidence concerns the gene LAIR1 and neoplasm.